Research area · week to 3 Oct 2026

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Moving in New England Journal of Medicine.

Moved this week: 1

Rebuilt 3 October 2026 at 2:01 pm AEST

Moved this week

Everything that moved →

Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.
New England Journal of Medicine · 9 July 2026 · Randomized Controlled Trial
Read the brief in JClub
- 21 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41812190
Open in JClub

Latest in Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Newest first · last 60 days

Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance.
Nature Genetics · 30 Sept 2026 · Journal Article
Lineage transformation to squamous identity enables KRAS inhibitor resistance in mouse lung adenocarcinoma models, independent of KRAS/MAPK pathway reactivation.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42816600
Open in JClub
Probability of causation in individual workers: Lung cancer due to occupational exposure to asbestos
medRxiv · 30 Sept 2026 · Preprint
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.02.06.26345596
Open in JClub
Single cell transcriptomics in a treatment-segregated cohort exposes a STAT3-regulated therapeutic gap in idiopathic pulmonary fibrosis
bioRxiv · 17 Sept 2026 · Preprint
Read the brief in JClub
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.1101/2025.06.16.659944
Open in JClub
Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment.
Nature Biotechnology · 7 Sept 2026 · Journal Article
Six proteomic aging clocks consistently predicted lower biological age in a 12-week clinical trial of rentosertib for idiopathic pulmonary fibrosis.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42706338
Open in JClub
HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER).
Gut · 7 Sept 2026 · Meta-Analysis
Adding peg-IFN to nucleos(t)ide analogue therapy achieves HBsAg loss in up to 38% of chronic hepatitis B patients with low initial HBsAg levels.
- Open access
- 5 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41198171
Open in JClub
Mechanisms of acquired resistance to osimertinib in EGFR T790M-Positive lung adenocarcinoma.
Frontiers in Genetics · 4 Sept 2026 · Journal Article
Heterogeneous resistance mechanisms, including EGFR mutations, bypass signaling, and transformation, emerge in EGFR T790M-positive lung adenocarcinoma after 14.2 months of osimertinib treatment.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42757013
Open in JClub
MAPK13 controls structural remodeling and disease after epithelial injury
bioRxiv · 28 Aug 2026 · Preprint
MAPK13 regulates epithelial stem cell-driven remodeling and disease, with knockout mice showing protection against hyperplasia and immune activation after injury.
- Open access
- 6 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.1101/2024.05.31.596863
Open in JClub
Chronic TGFB1 Signaling Drives Aberrant Alveolar-Basaloid Metaplasia through a KRT17-Stratifin migratory complex
bioRxiv · 28 Aug 2026 · Preprint
Read the brief in JClub
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.05.17.724675
Open in JClub
Natural History of Fibrotic Interstitial Lung Disease using AI-driven Test-free Assessment of Routine EHR
medRxiv · 22 Aug 2026 · Preprint
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.08.19.26360827
Open in JClub
Mapping the common and rare variant genetic risk landscape for pulmonary fibrosis with and without family history
medRxiv · 19 Aug 2026 · Preprint
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.05.15.26351995
Open in JClub
Targeting the Oxysterol Receptor GPR183 to Mitigate Fibrogenesis in Idiopathic Pulmonary Fibrosis
bioRxiv · 14 Aug 2026 · Preprint
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.08.09.743811
Open in JClub
Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer.
New England Journal of Medicine · 13 Aug 2026 · Randomized Controlled Trial
Selpercatinib significantly improves 2-year event-free survival in early-stage RET fusion-positive NSCLC, reaching 92% in stage II/IIIA patients compared to 61% with placebo.
- 2 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42223087
Open in JClub
Zinc displacement and metabolic interference: cobalt ion-mediated therapy for broad-spectrum CRKP-resistant pneumonia via inhalable microspheres.
Nature Communications · 12 Aug 2026 · Journal Article
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42717206
Open in JClub

Follow this area in the app

Journals this month

All journals →

Moving areas, week to 3 Oct 2026

All research areas →

Read

Moved this week

Latest in Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Browse JClub